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Abstract
Proportional hazards are a common assumption when designing confirmatory clinical trials
in oncology. This assumption not only affects the analysis part but also the sample size
calculation. The presence of delayed effects causes a change in the hazard ratio while the
trial is ongoing since at the beginning we do not observe any difference between treatment
arms and after some unknown time point, the differences between treatment arms will start
to appear. Hence, the proportional hazards assumption no longer holds and both sample size
calculation and analysis methods to be used should be reconsidered. The weighted log-rank test
allows a weighting for early, middle and late differences through the Fleming and Harrington
class of weights, and is proven to be more efficient when the proportional hazards assumption
does not hold. The Fleming and Harrington class of weights, along with the estimated delay,
can be incorporated into the sample size calculation in order to maintain the desired power
once the treatment arm differences start to appear. In this article, we explore the impact
of delayed effects in group sequential and adaptive group sequential designs, and make an
empirical evaluation in terms of power and type-I error rate of the of the weighted log-rank
test in a simulated scenario with fixed values of the Fleming and Harrington class of weights.
We also give some practical recommendations regarding which methodology should be used in
the presence of delayed effects depending on certain characteristics of the trial.
Keywords: adaptive designs; confirmatory trials; delayed effects; immuno-oncology agents;
weighted log-rank.
1 Introduction
In drug development, randomized controlled trials remain the gold standard to confirm efficacy
and safety of novel drug candidates. Often phase III trials embed formal interim analyses to allow
studies to be stopped earlier for futility if the novel drug is not efficacious or for efficacy if the
treatment effect is overwhelmingly positive.
Immuno-oncology (IO) is a rapidly evolving area in the development of anti-cancer drugs. IO
agents can have effect on both the human immune system and the tumor microenvironment. By
doing so, the tumors may be eradicated from the host or disease progression may be delayed. The
effect of an IO agent is not typically directed to the tumor itself; it instead boosts or releases the
brake from the patients immune system, and this positive effect may not be observed immediately.
1
ar
X
iv
:1
80
6.
11
29
4v
2 
 [s
tat
.M
E]
  9
 D
ec
 20
18
The lag between the activation of immune cells, their proliferation and impact on the tumor is
described in the literature as a delayed treatment effect. Some patients may not derive clinical
benefit before their disease progresses while others may derive sustained response or control of their
disease. The primary endpoints often used for confirmatory phase III studies in oncology are time
to event: progression free survival (PFS) and overall survival (OS). PFS is defined as time from
randomization until disease progression or death and OS is defined as time from randomization until
death from any cause. The delayed treatment effect may translate to inferior or equal PFS or OS
compared to control treatment in the first months of therapy and superior survival thereafter leading
to non-proportionality of hazards in the experimental and control arms of study. Therefore, the
original design based on a proportional hazards assumption will lead to an underpowered study and
hence both the sample size calculation and the analysis methods to be used should be reconsidered
[1].
A weighted version of the log-rank test that incorporates the Fleming and Harrington class of
weights [2], allows tuning the two parameters (ρ, γ) depending on if we expect early, middle or late
delays, is proposed in the literature to increase the power at the end of the trial. However, tuning
these parameters is not straightforward, since a misspecification may cause an even larger power
drop with respect to the log-rank test.
The Fleming and Harrington class of weights, along with the estimated delay, can be incorpo-
rated into the sample size calculation in order to maintain the desired power once the treatment
arm differences start to appear (see [3]).
In this article we make an empirical evaluation of the impact of having a delayed effect on power
and type I error rate in the design of a confirmatory phase III study with an IO agent used in
combination with a standard of care, assuming a range for delay time. We assess the performance
of the weighted log-rank test as an alternative to the log-rank test given it allows weighting of
late differences and the potential gain power under non-proportional hazards. The evaluation is
made for both group sequential and adaptive group sequential designs with fixed values of the
Fleming and Harrington class of weights. We also give some practical recommendations regarding
the methodology to be used in the presence of delayed effects depending on certain characteristics
of the trial.
The manuscript is organized as follows. In section 2, we describe the weighted log-rank test and
derive derive the sample size calculation formula needed to incorporate the estimated delay and the
Fleming and Harrington class of weights, and we introduce the combination test statistic that will
be necessary when doing sample size re-assessment. In section 3 we briefly describe group sequential
and adaptive group sequential designs, emphasizing two popular methods used to do sample size
re-assessment. In section 4, we describe the simulated example.
2 Methods
In this section we describe the statistical methodology we review in this article. In sections 2.1 and
2.2 we present the weighted log-rank test and derive an optimal sample size when using this test
following [3]. This sample size derivation is presented as an alternative to the Schoenfeld’s formula
[4], which is normally used when calculating the necessary sample size in confirmatory trials. In
section 2.3 we introduce the combination test statistic, which will be necessary when we perform
sample size re-estimation in adaptive group sequential designs.
Let T be a vector that contains the event times, ti, i = 1, 2, . . . , D, between the patients’ enroll-
ment date and the patients’ final event date, tD, such that t1 < t2 < · · · < tD. Let the number of
events at time ti be denoted as di, the total number of patients at risk at that time be denoted as
ni, and the effect delay (in months) be denoted as . As previously described if t <  both survival
curves go in parallel and once t ≥ , the survival curves will start diverging. Hence, we assume the
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following density functions fj(t), survival functions Sj(t) and hazard functions hj(t) for the control
group (j = 1) and for the experimental group (j = 2):
f1(t) = λ exp(−λt), S1(t) = exp(−λt) and h1(t) = λ,
f2(t) =
{
λ exp(−λt)
cψλ exp(−ψλt) , S2(t) =
{
exp(−λt)
c exp(−ψλt) and h2(t) =
{
λ if 0 ≤ t < 
ψλ if t ≥  ,
(1)
where c = exp
[
ψλ
(
1
ψ−1
)]
so that
∫∞
0
f2(t)dt = 1. This way, we assume a step function for the
hazard ratio where from time 0 to , the hazard ratio is equal to 1, and from time  the hazard ratio
is equal to 1/ψ.
In this article we assume that the control group receives the standard of care and the experi-
mental group receives a combination of the standard of care plus the IO agent which causes the
delayed effect. Hence, any observed difference from time 0 until time  is random. The conclusions
we obtain are only applicable to studies where a similar assumption is made. Otherwise, we cannot
guarantee that from time 0 to time , both groups have a common survival function.
2.1 Weighted log-rank test
The weighted log-rank test is defined as
Zr =
∑D
i=1 ri(d1i − E(d1i))√∑D
i=1 r
2
iVar(d1i)
, (2)
where E(d1i) = n1i ×
(
di
ni
)
, Var(d1i) =
n1in2idi(ni−di)
n2i (ni−1)
and Zr
appx.≈ N(0, 1) under the null hypothesis
H0 : h1/h2 = 1.
[2] proposed the use of ri to weight early, middle and late differences through the G
ρ,γ class of
weighted log-rank tests, where the weight function at a time point ti is equal to
ri = Sˆ(ti)
ρ(1− Sˆ(ti))γ, (3)
where Sˆ(ti) corresponds to the Kaplan-Meier estimator.
Depending on the values of ρ and γ, we will have different weight functions that will emphasize
early differences (ρ = 1, γ = 0), middle differences (ρ = 1, γ = 1) or late differences (ρ = 0, γ = 1)
in the hazard rates or the survival curves. The parameter combination attributes equal weights
to all (ρ = 0, γ = 0) data values and hence does not emphasize any survival differences between
treatment arms. Moreover, with this parameter combination (2) corresponds to the usual log-rank
test.
As mentioned by [3], since we focus on the entire survival curve rather than the late difference,
valid inference requires pre-specification of ρ and γ prior to any data collection.
Prior specification of (ρ, γ) is always advisable for the trial integrity, although some authors (see
e.g., [5]) note that the value of (ρ, γ) can be modified at the interim analysis without type-I error
rate inflation. At the end of the trial, we are interested in estimating the hazard ratio across the
entire study, which is obtained through the standard Cox model [6]. Note however that there will
be a disconnect between the hazard ratio (i.e., the standard Cox model) and the weighted log-rank
test. To obtain an estimate based on the Cox model that corresponds to the weighted log-rank test
see [7].
In this article we focus on the use of the weighted log-rank test in confirmatory trials with
delayed effects. Other areas of use may include treatment switching, which is sometimes present
in confirmatory trials and also induces non-proportional hazards (see [8]). However, it is out the
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scope of this article to evaluate the performance of the weighted log-rank test under the presence
of treatment switching and further research on this matter would be necessary.
2.2 Sample size derivation for the weighted log-rank test
We introduce the optimal sample size derivation proposed by [3]. Assume that we recruit patients
during time T at a certain rate in a confirmatory trial where we aim to compare survival time be-
tween two groups (j = 1, 2): a control group, with a constant hazard over time, and an experimental
group, with a hazard that changes over time. The final analysis is performed at time T + τ after
the first patient is enrolled. The study period [0, T + τ ] is partitioned into M subintervals of equal
length {t0 = 0, t1, t2, . . . , tM = T + τ}. Let hj(ti) be the hazard function for group j at time ti and
Nj(ti) be the expected number of patients at risk for group j at time ti, where i = 0, . . . ,M − 1.
[9] showed that the weighted log-rank statistic is normally distributed with unit variance and
approximate expectation of
E =
∑M−1
i=0 Diri
(
φiθi
1+φiθi
− φi
1+φi
)
√∑M−1
i=0 Dir
2
i
φi
(1+φi)2
, (4)
where
θi =
h2(ti)
h1(ti)
, φi =
N2(ti)
N1(ti)
, Di = (h1(ti)N1(ti) + h2(ti)N2(ti)),
Nj(t0) = nwj, Nj(ti+1) = Nj(ti)
[
1− hj(ti)−
(
1
T + τ − ti
)
I{ti>τ}
]
,
(5)
wj represents the allocation ratio for group j, and ri corresponds to the Fleming-Harrington’s G
ρ,γ
class of weights where ri = (S(ti))
ρ(1 − S(ti))γ and S(ti) represents the pooled survival function.
Even though it was originally proposed by [10], [3] uses S(ti) = w1S1(ti) + w2S2(ti) as a substitute
for the pooled survival function, where Sj(ti) represents the survival function of group j at time ti.
However, as stated by [3], equation (4) can be equivalently expressed as
E = n
1
2E∗ = n
1
2
∑M−1i=0 D∗i ri
(
φiθi
1+φiθi
− φi
1+φi
)
√∑M−1
i=0 D
∗
i r
2
i
φi
(1+φi)2
 , (6)
where
D∗i = (h1(ti)N
∗
1 (ti) + h2(ti)N
∗
2 (ti)),
N∗j (t0) = wj, N
∗
j (ti+1) = N
∗
j (ti)
[
1− hj(ti)−
(
1
T + τ − ti
)
I{ti>τ}
]
,
(7)
Assuming that the weighted log-rank statistic is normally distributed with mean n
1
2E∗ and unit
variance, then for a power equal to 1− β and one-sided significance level α we have∣∣∣n 12E∗∣∣∣ = zα + zβ, (8)
where zα and zβ correspond to the α-th and β-th percentile of the standard normal distribution
respectively. The required sample size is calculated as
4
n =
(
zα + zβ
E∗
)2
, (9)
and the total expected number of events is equal to n×∑M−1i=0 Di.
2.3 Test statistic
We aim to test the null hypothesis, H0 :
h1
h2
= 1, against the alternative, H1 :
h1
h2
< 1. In the context
of group sequential designs, since we are only interested in early efficacy testing we make use of the
well known classical group sequential design methodology (see [11]) and make use of the O’Brien
and Fleming rejection boundaries. In the context of adaptive group sequential designs, we make
use of the independent increment property of the inverse normal method, which is an efficient way
of incorporating data of patients who where censored at interim analysis while ensuring type-I error
rate control (see [12]). The test statistic is defined as
Z∗ = ξ1Φ−1(1− p1) + ξ2Φ−1(1− p2), (10)
where p1 and p2 denote the separate stage p-values from stages 1 and 2, Φ
−1 denotes the inverse
of the standard normal distribution, and ξ1 and ξ2 are pre-specified weights such that ξ
2
1 =
n1
n1+n2
,
ξ22 =
n2
n1+n2
and where n1 and n2 represent the number of events observed in each stage. The null
hypothesis will be rejected at level α if Z∗ > Φ−1(1− α).
However, the inverse normal method is in general not valid when doing sample size re-assessment
if the adaptations depend on endpoints such OS or PFS (see [13]). We use the approach proposed
by [14] where, in equation (10), the first stage p-value is defined by the cohort of patients included
before the interim analysis and is calculated only at the end of the trial. This allows the inclusion
of all the events, but it prohibits early stopping for efficacy. See [15] for a detailed review of the
existing methods on this matter.
3 Group sequential and adaptive group sequential designs
In this section we aim to briefly describe how group sequential and adaptive group sequential designs
work. For a detailed definition and explanation of this methodology see [11].
3.1 Group sequential designs
The formulae presented in section 2.2 allow to obtain a sample size that maintains an acceptable
power at the end of the trial under the presence of delayed effects. However, a key condition is to have
some knowledge about the delay of the drug. Assuming we have this knowledge when designing the
confirmatory trial, we can implement a group sequential design with an interim analysis for efficacy.
Note that interim analysis for futility is not advised in the presence of delayed effect because of
high risk of stopping the study for futility even in scenarios that favor the alternative hypothesis.
A group sequential design with one interim analysis for efficacy is graphically described in Figure
1.
3.2 Adaptive group sequential design
Even though the sample size derivation described in section 2.2 guarantees that after a pre-specified
effect delay we will have an acceptable power at the end of the trial while controlling the type-I
error rate, we may have misspecified the delay value or maybe this value is unknown. Either way, an
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Figure 1: Graphical representation of a group sequential design with an interim analysis for efficacy
where ρ1 is the efficacy boundary at the interim analysis and ρ2 is the efficacy boundary at the final
analysis.
H0 is rejected H0 is rejected
H0 is not rejected
If z1 > ρ1 If z2 > ρ2
If z2 ≤ ρ2Interimanalysis
Final
analysis
adaptive group sequential design that allows interim analyses and sample size re-assessment would
be useful in case we expect a lack of statistical power at the end of the trial given the results at the
interim analyses. Hence, with this design we aim to recover the power lost due to misspecification
of the delay. As explained in section 2.3, to maintain type-I error rate control when the sample
size criteria is based on survival endpoints, the interim analysis is only used to do a sample size
re-assessment and not for early stopping. Because we need to distinguish between the effect at the
interim analysis and the effect at the final analysis, let δ1 be the hazard ratio at the interim analysis
and let δ be the hazard ratio at the end of the trial.
We now introduce two popular approaches for sample size re-assessment:
3.2.1 Mehta and Pocock’s “promising zone” approach [16]
[16] propose a method that adaptively increases the sample size when interim results are considered
“promising”. For that, we compute the conditional power at the interim analysis using δˆ1 rather
than the true δ1. The formula for the conditional power is defined as
CPδˆ1(z1, n˜2) = 1− Φ
(
zα
√
n2 − z1√n1√
n˜2
− z1
√
n˜2√
n1
)
. (11)
If the conditional power is within a certain pre-specified range that we consider promising, we
may re-estimate the sample size to recover the power lost due to the effect delay. The selection of
this range depends not only on the estimate of the effect delay but also on the budget of the sponsor
for this particular trial. For example, if we have an estimated effect delay between 3 and 7 months,
but we only have budget to guarantee 80% of power up to 5 months, the sponsor can choose to stop
the trial. Therefore, following [16], we partition the sample space of attainable CPδˆ1(z1, n˜2) values
into three zones:
1. Favorable: We consider the interim results to be in the favorable zone if CPδˆ1(z1, n˜2) ≥ 1−β.
In this zone, the study is sufficiently powered for the observed δˆ1 and therefore no sample size
re-estimation is required.
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2. Promising: We consider the interim results to be in the promising zone if 1−β > CPδˆ1(z1, n˜2) ≥
CPmin. In this zone, δˆ1 is close to δ1 but the study is not sufficiently powered and a sample
size re-estimation is required. Specifically, the sample size will be increased to
n˜∗2(z1) = min(n˜
′
2, n(z1)max), (12)
where nmax is the maximum sample size the sponsor is willing to enroll and n˜′2(z1) satisfies
that CPδˆ1(z1, n˜
′
2) = 1− β. Following [17], it is possible to show that
n˜′2 =
(
n1
z21
)(
zα
√
n2 − z1√n1√
n2 − n1 + zβ
)2
. (13)
3. Unfavorable: We consider the interim results to be in the unfavorable zone if the value of
CPδˆ1(z1, n˜2) < CPmin. The value of CPmin is pre-specified before the trial starts and it
depends on the prior knowledge about the effect delay. In this zone the interim results are
not promising and the sample size will not be re-estimated.
Type-I error rate is controlled following [18], where it is shown that the overall type-I error does
not increases if the sample size is only re-assessed when
CPδˆ1(z1) ≥ 0.5. (14)
3.2.2 Jennison and Turnbull’s “start small then ask for more” approach [19]
[19] made a detailed analysis of Mehta and Pocock’s “promising zone” approach.
One drawback of the “promising zone” approach is the use of δˆ1 in the construction of the
promising zone and sample size increase function. The reason is that δˆ1 is considered as a highly
variable estimate of δ1, and also because it is used twice in determining the conditional power that
underlies the sample size function: the first time through the value of z1 and the second time when
evaluating the conditional power at δ = δˆ1. This double use of δˆ1 was also pointed out by [20] who
recommends a careful inspection of the operating characteristics when using δ = δˆ1.
Another drawback of Mehta and Pocock’s “promising zone” approach is that, despite the type-I
error rate being controlled, because of the restriction showed in (14), the gain in power is relatively
small for the increases in the expected sample size. Moreover, [19] demonstrated that other alter-
natives such us a fixed sample design and a group sequential design have exactly the same power
curve and a lower expected sample size around the true value of δ.
To overcome the last limitation, [19] propose an optimal sample size calculation rule where we
need to find the value of n∗2 that maximizes the objective function
f(n∗2) = CPδˆ1(z1, n
∗
2)− η(n∗2 − n2), (15)
where η can be considered as “a tuning parameter that controls the degree to which the sample size
may be increased when interim data are promising but not overwhelming”.
[19] pointed out that even though the objective function given by equation (15) “concerns
conditional probabilities given the interim data, choosing a sample size rule to optimize this objective
function also yields a design with an overall optimality property expressed in terms of unconditional
power”. They show that
Pδˆ1(Reject H0)− ηEδˆ(N) =
∫
{CPδˆ(z1, n∗2(z1))− η(n∗2(z1)− n2)}fδˆ(z1)dz1, (16)
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where fδˆ(z1) represents the density of Z1 under δ = δˆ, and since we maximize equation (15), for
every z1, we also maximize the right hand side of equation (16). Moreover, it is possible to show
that this sample size rule has the minimum expected sample size among all rules that achieve the
sample power under δ = δˆ.
In algorithms 1 and 2 we describe how to implement the reviewed methodology in case the
sample size needs to be re-assessed.
Algorithm 1 Group sequential adaptive design using Mehta and Pocock’s “promising zone” ap-
proach.
1: procedure
2: Recruit up to n patients and when n1 events are observed analysis compute CPδˆ1(z1, n˜2)
3: Calculate the number of events n˜′2 and total sample size necessaries for the second stage.
4: Recruit patients until n˜′2 events are observed.
5: Compute Z∗ = ξ1Φ−1(1− p1) + ξ2Φ−1(1− p2) . p1 is calculated at the final stage using
only the patients enrolled before the interim analysis.
6: if (Z∗ > Zα) then
7: Outcome ← 1 . H0 is rejected at the final analysis
8: else
9: Outcome ← 0 . H0 is not rejected at the final analysis
10: end if
11: return Outcome
12: end procedure
Algorithm 2 Group sequential adaptive design with one interim analysis for efficacy using Jennison
and Turnbull’s “start small then ask for more” approach.
1: procedure
2: Recruit up to n patients, and when n1 events are observed do the interim analysis.
3: Calculate the number of events n∗2 and total sample size necessaries for the second stage.
4: Recruit patients until n∗2 events are observed.
5: Compute Z∗ = ξ1Φ−1(1− p1) + ξ2Φ−1(1− p2) . p1 is calculated at the final stage using
only the patients enrolled before the interim analysis.
6: if (Z∗ > Zα) then
7: Outcome ← 1 . H0 is rejected at the final analysis
8: else
9: Outcome ← 0 . H0 is not rejected at the final analysis
10: end if
11: return Outcome
12: end procedure
4 Simulation setup
We implement the methodology described in sections 2 and 3 on a scenario that tries to imitate a
realistic phase III trial with delayed effects in oncology.
Survival data for the control arm is simulated using an exponential distribution while data for
the experimental arm is simulated using a distribution that is piece-wise exponential (see equation
(1)). Under proportional hazards, we assume that the control arm has a median survival of 6
months while the experimental arm has a median survival of 9 months. Hence, the hazard ratio is
equal to 0.667. However, under the presence of delayed effects we assume a step function for the
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hazard ratio where it will be equal to 1 until a certain time point , and then it will be at its full
effect after . This means that while the control arm will keep its median survival of 6 months, the
median survival of the experimental arm will no longer be 9 months because of the delayed effect.
We establish a total study duration of 25 months, a total enrollment period of 17.5 months,
randomization ratio 1:1, a power of 90% and a one-sided level α of 2.5%.
Clinical trial enrollment follows a Poisson distribution with rate of 10 patients per month.
Plotting the cumulative distribution function of a Poisson distribution of these characteristics using,
for instance, the R function ecdf(), it is straightforward to see that after 17.5 months almost all the
patients, if not all, are enrolled in the trial. Results are obtained running 200,000 simulated trials.
R code is showed in the appendix explaining how to simulate survival data under the presence of
delayed effects.
In Table 1 we show the information fraction, the cumulative α spent, the O’Brien and Flem-
ing efficacy boundaries, and the boundary crossing probability at each look. Recall that these
boundaries are only used in the context of group sequential designs where the sample size is not
re-assessed and they are calculated based on the information fraction only. If the sample size needs
to be re-assessed, we employ different methodology (see section 2.3)
Table 1: Information fraction, the cumulative α spent, the efficacy boundaries, and the boundary
crossing probability at each analysis in the group sequential design we use as an example.
Look #
Information
Fraction
Cumulative α
spent
Efficacy
boundary Z
Boundary crossing
probability (incremental)
1 0.75 0.01 2.34 0.688
2 1 0.025 2.012 0.212
For both the group sequential and the adaptive group sequential designs, we estimate the em-
pirical power and the empirical type-I error rate at the final analysis. In the context of group
sequential designs, let Ztest be the Z-statistic obtained at the end of the trial and Z2 be the efficacy
boundary of the final analysis presented in Table 1. In scenarios under the alternative hypothesis,
the empirical power is defined as
Power =
1
M
m∑
i=1
I[Ztest > Z2], (17)
whereas in scenarios under the null hypothesis, (17) is the empirical type-I error rate. In the context
of group sequential adaptive designs, in equation (17), Ztest needs to be substituted by Z
∗ and Z2
needs to be substituted by Zα in order the implement the inverse normal method described in
section 2.3.
5 Results
In this section we evaluate the repercussion of delayed effects on the power and the type-I error rate
in group sequential and adaptive group sequential designs. The results presented in this section are
based on the simulated scenario described in section 4.
Because one of the purposes of this work is to make a comparison between the log-rank test
and weighted log-rank test, in Table 2 we show, for different delay times, the required number of
events and the sample size using the parameter values (ρ = 0, γ = 0) and (ρ = 0, γ = 1) following
the formulas presented in section 2.2. As we can see, under proportional hazards the parameter
combination (ρ = 0, γ = 0) is more efficient since it requires 258 events whereas the parameter
combination (ρ = 0, γ = 1) requires 369 events to maintain 90% of power. However, with 5 months
9
delay, the parameter combination (ρ = 0, γ = 1) becomes more efficient since it requires 741 events
whereas the parameter combination (ρ = 0, γ = 0) requires 1436 events to maintain 90% of power.
Table 2: Sample size calculation for different effect delay times using the parameter values (ρ =
0, γ = 0) and (ρ = 0, γ = 1) using the sample size formulae reviewed in Section 2.2.
Delay (months) 0 1 2 3 4 5
(ρ = 0, γ = 0)
# of events 258 359 492 686 986 1436
# of patients 330 456 621 860 1228 1777
(ρ = 0, γ = 1)
# of events 369 376 406 468 578 741
# of patients 472 478 512 587 719 917
5.1 Group sequential design
In Figure 2 we show the empirical power and type-I error rate at the final analysis for a wide range
of ρ and γ combinations with the design characteristics presented in section 4 assuming no delayed
effect in the sample size calculation. As expected, the results show that the parameter combination
(ρ = 0, γ = 0) achieves 90% of power and 2.5% type-I error at the final analysis. However, as the
delay increases, we observe that power drops faster than other combinations of ρ and γ as the effect
delay increases. Other combinations like (ρ = 0, γ = 1) have less power under proportional hazards
but maintain higher power as the effect delay increases. These results are expected since low values
of ρ and high values of γ weight late differences, which is the situation we recreate in this simulated
trial. However, combinations that weight late differences produce a slight type-I error rate inflation
as we can observe in Figure 2, right image.
Using the methodology described in section 2.2, if we incorporate an estimate of the effect delay
in the sample size calculation, we are able prevent the power to drop until that specified moment.
This is shown in Figure 3, where for each delay time we calculate the sample size necessary to
achieve 90% power taking the delay into account. Moreover, when correctly specifying the effect
delay, we observe that not only low values of ρ and high values of γ achieve high power. However,
in terms of type-I error rate, we observe the same slight type-I error rate inflation we observed in
Figure 2 for low values of ρ and high values of γ.
To control the type-I error rate, we propose to use a similar approach as the one used by [21] in
which, although in a different context, instead of calculating the sample size for α = 2.5%, a lower
value of α is fixed so the final type-I error rate is maintained at 2.5%.
10
Figure 2: Empirical power and type-I error for a wide range of combinations of ρ and γ at the final
analyses with different effect delay times and a unique sample size calculated assuming proportional
hazards. In black, the five combinations with less cumulative power loss over time, in dark grey the
power loss of the log-rank test (ρ = 0, γ = 0) over time, and in light grey the power loss of the rest
of the combinations.
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Figure 3: Empirical power (left) and type-I error (right) for a wide range of combinations of ρ and
γ at the final analyses with different effect delay times and a different sample size for each delay
time. In the left image, in black, the five combinations with highest mean power over time. In dark
grey the log-rank combination (ρ = 0, γ = 0) and in light grey the rest of the combinations. In the
right image, in black the type-I error of the five combinations with highest mean power over time.
In dark grey the log-rank combination (ρ = 0, γ = 0) and in light grey the rest of the combinations.
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5.2 Adaptive group sequential design
In this section we show how performing a sample size reassessment we recover some of the power
lost due to the delayed effect. As in the previous section, the results presented here make use of the
simulated example described in section 4. However, rather than using a wide range of combinations
of ρ and γ, we use the combination (ρ = 0, γ = 1) since we believe it is the most suitable combination
for this kind of setting.
In Figure 4 we present the empirical type-I error (top-left image), empirical power (top-right
image), percent of times we re-adjust the sample size (bottom-left image) and the ratio between
new sample size and original sample size (bottom-right image) for different effect delays using the
weighted log-rank test with the parameter combination (ρ = 0, γ = 1) using the promising zone
approach proposed by [16].
We employ three different promising zone lower bounds (0.5, 0.1, 0.001) and compare their
operating characteristics against a design that does not reassess the sample size. Without any
sample size reassessment, the power is below 80% after 3 months. Using a promising zone lower
bound of 0.5, the power will be below 80% after 3.5 months. However, if the promising zone
lower bound is 0.1 or 0.001, the power will be below 80% after 4 and 6 months, respectively. As
discussed in the literature (see [19]) we corroborate that the gains when using a lower bound of 0.5
is practically negligible and the greatest gains in power are likely to be found outside the region
defined by [16].
In terms of type-I error, we observe it is perfectly controlled for any value of the promising
zone lower bound. However, note that we implemented our previously described proposal in which
instead of calculating the sample size for α = 2.5%, a lower value of α is fixed so the final type-I
error rate is maintained at 2.5%. Otherwise we would see the same slight type-I error rate inflation
we identified in the Figures 2 and 3 due to the ρ and γ parameters that we employ.
In terms of percent of times we fall in the promising zone, when the lower bound is 0.5, the
probability of re-adjusting the sample size reaches its maximum value, which is around 15% at
4 months. If the lower bound is 0.1, the probability of re-adjusting the sample size reaches its
maximum value, which is around 35% between 4 and 5 months. Last, if the lower bound is 0.001,
the probability of re-adjusting the sample size reaches its maximum value, which is close to 70% at
6 months.
In terms of how much we need to increase the sample size with respect to the original sample
size every time we fall in the promising zone, we observe that if the lower bound is 0.5, we need
around 1.5 times the original sample size regardless the delay time. If the lower bound is 0.1, we
need around 2.5 times the original sample size also regardless the delay time. Last, if the lower
bound is 0.001, for a delay time t = 0, we need around 4.5 times the original sample size. For a
delay time t = 4 we need around 9 times the original sample size and for a delay time t = 6 we
need around 15 times the original sample size.
It is important to mention that, in practice, a promising zone lower bound of 0.001 may not
be possible to implement given the excessively increase in the number of events needed and the
consequent increase in the budget for the trial. However, we believe it is interesting to show that it
is possible to maintain a power of 80% for another three extra months, regardless of the additional
duration and expenses of the trial.
Last, in Figure 5 we make a comparison between the approaches of [16] and [19]. We selected
the promising zone’s lower bound 0.001 because it is the one that is more expensive to put into
practice and where greater differences are observed. As expected, the approach from [19] is able to
maintain the same power as the approach from [16]. However, in terms of how much we need to
increase the sample size with respect to the original sample size, [19] requires smaller sample size,
specially after 4 months of delay.
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Figure 4: Empirical type-I error rate (top left), empirical power (top right), percent of times sample
size is reassessed (bottom left) and ratio between the reassessed number of events and the original
number of events (bottom right) at different delay times, when the sample size is calculated assuming
no delay, using the “promising zone” approach.
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Figure 5: Empirical power and ratio between the reassessed number of events and the original
number of events when using the approaches from [16] and [19]
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6 Practical Considerations
In the previous sections we evaluated the impact of delayed effects in clinical trials and what
methodology exists in order to reduce it. However, we cannot conclude which methodology is
better in general terms because it will depend on many factors. In this section, we emphasize some
practical considerations regarding the use of the presented methodology.
The first question we tackled in this article in the use of the weighted log-rank test versus the
log-rank test in group sequential and adaptive group sequential designs. In the presence of known
delayed effects, we observed that the weighted log-rank test with parameter values (ρ = 0, γ = 1) is
the overall best choice, not only for the analysis but also for the sample size formula. We recall that
the use of these parameter values in the weighted log-rank test generates a slight type-I error rate
inflation and hence the value of α needs to be slightly decreased in order to achieve a final type-I
error rate of 2.5%.
In cases where the delayed effect is unknown or underestimated in the sample size calculation,
there exists methodology that re-adjusts the sample size in order to increase the power at the final
analysis. The use of each method will depend on the characteristics of the trial. From the two
methods we evaluated in the article, we observed that the proposal of [19] outperforms the proposal
of [16] in the sense that for the same power, [19] requires less sample size. However, with these
approaches it is possible to back-calculate the conditional power at the interim analysis if we know
the sample size increase recommended for the second stage of the trial. If this situation does not
compromise the integrity of the trial, we recommend the use of [19] as it is proven to be more
efficient. However, if the effect at the interim analysis has to remain masked, we propose the use of
a modified version of [16], which would work as follows.
We would establish a promising zone, as in the original method, in which we re-calculate the
sample size if the conditional power falls within a certain pre-specified range. The original method
would calculate a different sample size for each conditional power (or delay time). However, in order
to avoid back-calculations based on the second stage sample size, we propose to fix in advance the
sample size to be used in the second stage of the trial. To avoid having an underpowered trial,
we can fix the sample size increase assuming the lowest possible value for the conditional power
(or the highest delay time) of the promising zone. This value would represent the maximum fixed
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sample size increase, although with this approach, we will be overpowering the trial for almost all
values of the conditional power that fall in the promising zone. On the other hand, we can also
fix the sample size increase to the highest possible value for the conditional power (or the lowest
delay time) of the promising zone. This fixed value would represent the minimum fixed sample size
increase, although with this approach, we will be underpowering the trial for almost all values of
the conditional power that fall in the promising zone. This modification of the method proposed
by [16] is illustrated (using a toy example) in Figure 6.
In this case, even though the “safest” option would always be using the maximum fixed sample
size increase, we cannot give a recommendation since a large number of sample sizes between the
maximum and the minimum fixed sample size increases can be employed and the choice depends
on how much risk of having an underpowered study the sponsor is willing to take.
Figure 6: Fixed sample size increase illustration following a modified version of the “promising
zone” proposed by [16].
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7 Conclusions
In this article we evaluated the impact of delayed effects, in terms of power and type-I error rate,
in phase III clinical trials. We studied the use of the weighted log-rank test as an alternative to the
log-rank test in group sequential and adaptive group sequential designs. This includes not only the
analysis but also the incorporation of the Fleming and Harrington class of weights, as well as a delay
estimate, in the sample size calculations. Also, we reviewed two different sample size re-adjustment
methods, and explored which one is more efficient.
Results show that, in the presence of delayed effects when assuming proportional hazards, the
weighted log-rank test with parameter values (ρ = 0, γ = 1) was the best overall choice, as it was
the one that maintained a higher power as the delay increases. When incorporating the Fleming
and Harrington class of weights, as well as a delay estimate, into the sample size calculation, we
observed that the power remains until the delay estimate we provided and the difference in terms of
power between parameter values was not as big as under the assumption of proportional hazards,
although the parameter values (ρ = 0, γ = 1) were overall the best combination. Sample size re-
adjustment allows increasing the sample size at the interim analysis to lower the risk of failing to
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meet the study objective. We explored the operating characteristics of two popular approaches for
sample size re-adjustment: the “promising zone” approach by [16] and the “start small then ask for
more” approach by [19].
With the proposal from [16] it is possible to maintain the power high enough for the trial to be
valid. However, the proposal from [19] is proven to be more efficient as for the same power curve, it
requires less sample size. Nevertheless, there are situations in which having a “promising zone” may
be more beneficial. This is the case when the effect at the interim analysis has to remain masked
for integrity reasons. The problem is that it is possible to back-calculate the effect at the interim
analysis by knowing the sample size increase. Hence, in this article we propose a modified version
of the proposal from [16]. It does not require any modification of the original formulation. If a trial
has a conditional power that falls in a pre-specified promising zone, we apply a pre-specified fixed
sample size increase that will be used regardless the value of the conditional power as long as it
falls in the promising zone. With this approach, even though we maintain the effect masked at the
interim analysis, there is the risk of having an underpowered study if the fixed sample size increase
in not large enough. However, if we want to avoid that risk, we will need to recruit more patients
than necessary with the associated extra cost.
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Appendix
In this section of the manuscript we present the R code we used to simulate survival data for
confirmatory and for running a group sequential design with one interim analysis for efficacy under
the presence of delayed effects.
#Sample size
n = 330
#Overall number of events
nevents = 258
#Number of events at the interim analysis
nevents_look1 = 194
#Enrollment rate
enrollment_rate = 10
#Survival median of the control group
originalMedian1 = 6
#Survival median of the experimental group
originalMedian2 = 9
#Delay
epsilon = 2
#Parameters rho and gamma (remember that rho=0 and
#gamma=0 implies using the usual log -rank test).
prho = 0
pgamma = 0
#Interim analysis rejection boundary
rejectionBoundary1 = 2.339711
#Final analysis rejection boundary
rejectionBoundary2 = 2.011719
#Simulated trial number ’k’ (if you want to compute the power
#and type -I error of this design a for loop is needed since this code only
#simulates one clinical trial ).
k = 1
#We generate the survival times for all the patients. Note that because until
#the delayed effect kicks the hazard ratio is equal to one , and hence all the
#survival data is generated from the same exponential distribution.
event_time = rexp(n, rate = log(2)/originalMedian1)
#We generate the treatment arm.
group = c(rep(0, n/2),rep(1,n/2))
#We generate the enrollment times.
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enrollment_times = rpois(n,enrollment_rate)
#We select the treatment arm with immuno -therapy and if the survival
#time is larger than the moment where the delay kicks in (epsilon),
#we resample that value.
for(i in 1:n){
if(group[i] == 1 & event_time[i] > epsilon ){
event_time[i] = epsilon + rexp(1, rate = log(2)/originalMedian2)
}
}
#We create a variable containing what we call pseudo -survival times.
#It contains the sum of the enrollment time plus the survival time and
#we use it to establish the censoring threshold using the number of events
#required to do the interim analysis.
pseudo_surv = enrollment_times+event_time
#INTERIM ANALYSIS
#We sort our pseudo -survival variable and choose the time of
#the observation number that is equal to the number of events
#required to do the interim analysis.
threshold_censoring[k,1] = sort(pseudo_surv)[ nevents_look1]
#We create a variable to identify enrolled patients.
enrolled = ifelse(enrollment_times < threshold_censoring[k,1], 1, 0)
#We create a variable that contains the survival times taking
#into account the censoring status.
survival_time = ifelse(pseudo_surv > threshold_censoring[k,1],
threshold_censoring[k,1] - enrollment_times , event_time)
#We create a variable with the censoring status
censor = ifelse(pseudo_surv > threshold_censoring[k,1], 0, 1)
#We put all the variables together and keep only the enrolled
#patients for the analysis.
data.df1 <- data.frame(survival_time ,censor ,group ,enrolled)
data.df1 = data.df1[data.df1 [,4]==1 ,]
#We do the weighted log -rank test to reject or not the null hypothesis.
fit.wlr00_st1 <- wtdlogrank(Surv(survival_time , censor)~group ,
data = data.df1 , sided = 1, WtFun="FH", param=c(prho ,pgamma ))
#If z1 > rho1 (according to manuscript notation) we reject the
#null hypothesis that states that the hazard ratio is equal to one.
reject[k,1] = ifelse(abs(fit.wlr00_st1$Z) > rejectionBoundary1 , 1, 0)
#This is only to be sure that we account for the rejection at the interim
#of the null hypothesis in the final analysis as well , even though we
#don ’t technically do the final analysis because the hypothesis is
#rejected at the interim and the trial stopped.
if(reject[k,1] == 1){
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reject[k,2] = 1
next
}
#We now continue with the second stage of the trial if
#we didn ’t stop for efficacy.
#For the second stage we repeat the same procedure we did for the first stage.
#However , this time we do the calculations with the censoring threshold
#obtained when the total number of events is reached.
threshold_censoring[k,2] = sort(pseudo_surv)[ nevents]
enrolled = ifelse(enrollment_times < threshold_power[k,2], 1, 0)
survival_time = ifelse(pseudo_surv > threshold_censoring[k,2],
threshold_censoring[k,2] - enrollment_times , event_time)
censor = ifelse(pseudo_surv > threshold_censoring[k,2], 0, 1)
data.df2 <- data.frame(survival_time ,censor ,group ,enrolled)
data.df2 = data.df2[data.df2 [,4]==1 ,]
fit.wlr00_st2 <- wtdlogrank(Surv(survival_time , censor)~group ,
data = data.df2 , sided = 1, WtFun="FH", param=c(prho ,pgamma ))
reject[k,2] = ifelse(abs(fit.wlr00_st2$Z) > rejectionBoundary2 , 1, 0)
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